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ABSTRACT 
 
The WHO Regional Committee for Europe adopted the goal of eliminating indigenous measles 
transmission in 1998. In 2005, the Regional Committee expanded this commitment to include 
rubella and set a date for the elimination of both diseases by 2010. Although Member States 
did make progress, through the implementation of a strategic plan, the goal was not 
achieved. The WHO Regional Committee for Europe acknowledged at its sixtieth session 
(2010) that the regional goal of eliminating measles and rubella is achievable, and set a new 
target date of 2015.  
In the document Eliminating measles and rubella and preventing congenital rubella infection, 
WHO European Region strategic plan 2005–2010, key strategies are identified to meet the 
targets for interrupting transmission of indigenous measles and rubella and preventing 
congenital rubella infection. Strengthening surveillance systems by vigorous case 
investigation, including laboratory confirmation, is one of these key strategies. 
In line with the elimination goal, Surveillance guidelines for measles, rubella and congenital 
rubella syndrome in the WHO European Region are intended to provide technical advice on 
the design and implementation of surveillance programmes. Surveillance indicators defined 
in these guidelines will be critical for assessing whether Member States have achieved the 
level of disease surveillance necessary for documenting elimination of indigenous measles 
and rubella transmission, and verifying that the Region’s elimination objectives have been 
reached. 
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1 Introduction 
The European Region of the World Health Organization (WHO) has adopted the goal of 
eliminating endemic measles and rubella, which will also lead to elimination of congenital 
rubella syndrome (CRS). In 2005, in resolution EUR/RC55/R7, the WHO Regional 
Committee for Europe acknowledged that measles and rubella can be eliminated in the 
WHO European Region and that congenital rubella infections can be prevented by using 
combined measles and rubella vaccines in a routine two-dose vaccination schedule within 
childhood immunization programmes, by achieving and maintaining high coverage and by 
targeting susceptible populations, including women of childbearing age (1). In 2010, the 
WHO Regional Committee for Europe recommitted to these goals, and changed the target 
date for elimination from 2010 to 2015 (2). In 2012, the Global Measles Initiative was 
expanded to include the rubella goal and a new global strategic plan for measles and rubella 
was adopted (3). 
 
The key strategies for achieving measles and rubella elimination in the WHO European 
Region are as follows: 
 Achieve and sustain very high vaccination coverage (≥95%), with two doses of 
measles vaccine and at least one dose of rubella vaccine administered through high-
quality routine immunization services. 
 Provide measles and rubella vaccination opportunities covering high-risk groups, 
including supplementary immunization activities, for all populations susceptible to 
measles and/or rubella. 
 Strengthen surveillance systems through rigorous case investigation and laboratory 
confirmation of suspected sporadic cases and outbreaks. 
 Improve the availability and use of high-quality, evidence-based information for 
health professionals and the public on the benefits and risks associated with 
immunization against measles and rubella. 
 
1.1 Objectives of surveillance and 
programme monitoring 
The purpose of disease surveillance is to provide information for public health action, i.e. to 
guide the planning, implementation and evaluation of public health interventions and 
systems (4). It is important that disease surveillance is considered within the overall 
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information needs of an immunization programme, and that it supports effective programme 
management. This includes information about: 
 cases and clusters of the disease (epidemiological surveillance); 
 vaccination-related adverse events (immunization safety); 
 routine immunization coverage (quality of programme delivery); and  
 the possible accumulation of susceptible persons (epidemiological surveillance, 
outbreak investigation and seroprevalence surveys). 
 
As the control of measles and rubella becomes more effective and countries approach the 
point at which these diseases can be eliminated, surveillance systems will be required to 
detect and facilitate the investigation and laboratory confirmation of all suspected cases. 
Such systems need to be sensitive, specific and case-based and capable of determining 
whether cases can be linked, i.e. whether sustained transmission is occurring. Since children 
and adults of any age can be susceptible to measles and rubella, and cases may occur at 
any time of the year as a result of importations, surveillance for these diseases must be 
carried out nationwide, among the general population, all year round.  
 
As part of an elimination strategy, surveillance for measles and rubella has two objectives: 
 
1. To detect, investigate and characterize sporadic cases and outbreaks/chains of 
transmission, to: 
 ensure proper management of cases and contacts; 
 understand the reasons for the occurrence and transmission of disease 
(e.g. importation, failure to vaccinate or failure of the vaccine);  
 assess the sustainability of transmission (outbreak size, duration of transmission); 
 identify populations at risk of transmission; and 
 ensure a rapid and appropriate public health response. 
 
2. To monitor disease incidence and circulation of the virus in order to:  
 assess the current level of disease incidence and virus circulation; 
 identify the geographical origin of circulating viruses (imported or endemic); 
 provide information for priority-setting, planning, implementation and resource 
allocation for prevention programmes, and for evaluating control measures; 
 identify changes in risk groups and disease epidemiology; 
 assess the circulation of virus genotypes at national, regional and global levels; and 
Surveillance Guidelines for Measles, Rubella and Congenital Rubella Syndrome in the WHO European Region  
Update December 2012 
Introduction 6 
 
 assess and document progress towards elimination, providing information for 
verification of measles and rubella elimination. 
 
Monitoring and evaluation of the surveillance system will be critical for assessing its 
performance by providing evidence of the validity of the data (i.e. the absence of confirmed 
cases is attributable to the absence of disease rather than to underdetection or 
underreporting) and identifying areas where surveillance needs to be strengthened. 
 
In addition to disease surveillance, reliable systems to monitor immunization coverage and 
quality and safety of vaccines should be in place at national and subnational levels. Detailed 
information on cold-chain monitoring, injection safety and surveillance for adverse events 
following immunization can be found in other WHO documents at the Immunization, 
Vaccines and Biologicals (IVB) document centre1.  
 
Elimination requires the achievement and maintenance of low levels of susceptibility in the 
population of all ages at each administrative level. The objectives of monitoring susceptibility 
are to: 
 identify population subgroups at higher risk for disease transmission based on age, 
social or geographical characteristics, and evaluate the risk of outbreaks in these 
groups; and 
 provide information for the planning of interventions to reduce susceptibility in 
identified population subgroups and thus avoid outbreaks. 
 
The epidemiology of measles and rubella in the European Region varies between countries, 
reflecting different challenges in controlling these diseases. Despite the availability of highly 
effective vaccines and very good overall vaccine coverage in most of the 53 Member States, 
specific population subgroups remain susceptible to these diseases (5). Some young adults 
remain susceptible to measles and rubella, as they may not have been vaccinated, or may not 
have contracted the diseases because of the decreasing incidence of measles and rubella 
following vaccine introduction. In many countries, immunization programmes may not 
adequately reach minorities or geographically or socially marginalized populations. People 
holding specific philosophical or religious beliefs may be reluctant to be immunized or actively 
oppose vaccination (6-9). These and other groups may influence others with misinformation 
about the safety and effectiveness of vaccines. Susceptible individuals are often 
geographically clustered, creating “pockets of susceptibility” at a greater risk of large 
                                                          
1
 See http://www.who.int/immunization/documents/en/, accessed 15 December 2012. 
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outbreaks. At the same time, increased population movements related to migration, 
immigration and work-related or leisure-related travel, increase the potential for disease 
transmission from countries with a high incidence of measles or rubella to countries and 
populations where the incidence is low or the disease has been eliminated. Lack of health care 
worker awareness of the benefits of vaccination and lack of strong provider recommendations 
may be contributing to suboptimal vaccination coverage in some countries. A high level of 
vaccine coverage (≥95%) with two doses of measles vaccine and at least one dose of 
rubella vaccine must be achieved among susceptible subgroups if measles and rubella are 
to be eliminated in the Region. 
 
The elimination of measles and rubella is defined as the absence of endemic measles or 
rubella transmission in a defined geographical area (e.g. region) for at least 12 months in the 
presence of a well performing surveillance system (10). However, imported cases may still 
occur in elimination settings. 
 
Progress towards elimination should be monitored and supported by a robust and sensitive 
surveillance system. Information provided by the surveillance system, along with the 
information on population immunity, will be crucial for verification of measles and rubella 
elimination in the Region. Verification of elimination will require the absence of sustained 
transmission throughout the Region for a period of at least 36 months. The system’s 
performance should be assessed by surveillance indicators, which are discussed later in this 
document. 
 
The present document, Surveillance guidelines for measles, rubella and congenital rubella 
syndrome in the WHO European Region, primarily addresses issues related to disease 
surveillance and monitoring of progress towards elimination in the Region. This document 
provides guidance and recommendations, and describes best practices for surveillance for 
measles, rubella and CRS. It is intended for national programme managers, and those 
responsible for such surveillance, to aid them in the development of their country-specific 
surveillance plans and to provide a framework for monitoring progress and documentation 
for verification of the elimination of measles and rubella in the Region. This document does 
not directly address clinical aspects of measles and rubella, e.g. clinical management of 
measles cases or of pregnant women exposed to rubella. 
 
  8 
 
2 Measles, rubella and CRS: 
disease description, 
epidemiology and diagnosis 
2.1 Measles 
Measles is one of the most contagious viruses, with a secondary attack rate among 
susceptible individuals higher than 90%. The virus can be transmitted in the air (aerosolized) 
in respiratory droplets, or by direct or indirect contact with the nasal and throat secretions of 
infected persons. Individuals with measles are considered infectious from four days before to 
four days after the onset of rash (11). Following exposure, the incubation period before onset 
of the first symptoms is usually 10–12 days. The rash usually appears 14 days after exposure 
(range 7–18 days) (11, 12)2. 
 
Approximately 30% of reported cases of measles involve one or more complication. In 
developed countries these include otitis media (7–9%), pneumonia (1–6%), diarrhoea (6%), 
blindness and post-infectious encephalitis (1 per 1000 cases). The risk of serious measles 
complications is higher in infants and adults. A less common but very serious complication is 
subacute sclerosing panencephalitis (1 per 100 000 cases) (12). 
 
Measles remains a leading cause of death globally among young children, despite the 
availability of safe and effective vaccines for over 40 years. An estimated 139 000 children 
died worldwide from measles in 2010, a 74% reduction compared with 2000 (14). The 2005 
measles mortality reduction goal established by WHO and the United Nations Children’s Fund 
(UNICEF), which was to reduce the number of measles deaths by 50% from 2000 levels, has 
now been achieved (15, 16). There is a new goal to achieve a 95% reduction worldwide by 
2015, primarily by targeting children in the WHO regions with the highest number of measles 
deaths (Africa and South-East Asia) (3). 
 
                                                          
2
 The incubation period from exposure to the onset of rash is with a range of 7–18 days, but rarely, as long as 
19–21 days. Use of immunoglobulins in the early stage of infection can prolong incubation. Some countries use 
21 days as the longest incubation period (11, 12, 13). 
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In settings where measles remains endemic, transmission of the virus shows a seasonal 
trend: in temperate areas, the most intense virus transmission usually occurs in late winter 
and spring. Before vaccination programmes, childhood infection was almost universal. 
Measles epidemics occurred in approximately four-year cycles, with periods of very high 
incidence alternating with low-incidence inter-epidemic periods. With the introduction and 
increased coverage of measles vaccination, the incidence of the disease during epidemic 
periods has fallen and the intervals between epidemics have lengthened. Very high levels of 
population immunity have led to the elimination of the disease in many countries, but if this 
level of population immunity is not maintained, the cyclical pattern of measles outbreaks will 
reappear.  
 
In contrast to developing countries, the majority of cases in many European countries occur 
in adolescents and adults (17, 18). In most countries of the Region, measles vaccination 
coverage and population immunity among the general population are high and the cyclical 
pattern of measles is not seen. However, there are still susceptible groups in most countries. 
While some of these susceptible individuals live within communities with high levels of 
population immunity to measles and rubella, and are therefore at low risk of exposure to wild 
measles virus following an importation, others live in settings where the risk of exposure and 
further transmission between individuals is very high after the virus is introduced.  
 
The case–fatality ratio for measles is highest in infants aged under 12 months. In developed 
countries, the case–fatality ratio is 0.05-0.1 per 1000 cases, much lower than in developing 
countries where it can be 3–6% (15, 19). Malnutrition and severe immunodeficiency (e.g. as 
a consequence of an advanced infection with human immunodeficiency virus) are risk 
factors for complications, including death. 
 
2.1.1 Laboratory diagnosis of measles 
 
In the European Region, where the incidence of measles is low, a clinical diagnosis of 
measles in the absence of a confirmed outbreak has a low positive predictive value, and 
clinical signs are unreliable as the sole criteria for diagnosis. A number of other infections 
can present with a rash resembling measles, therefore laboratory assessment is required for 
accurate diagnosis.  
 
Measles-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) are both produced 
during the primary immune response and can be detected in the serum within days of rash 
onset, using a sensitive enzyme-linked immunosorbent assay (ELISA). Approximately 70% 
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of measles cases are IgM-positive at 0–2 days after the rash onset, and 90% are positive 
3-5 days after rash onset. IgM antibody levels peak after 7–10 days and then decline, being 
rarely detectable after 6–8 weeks. IgG antibody levels peak within three weeks and persist 
long after the infection. Serum and secretory immunoglobulin A (IgA) antibodies are also 
produced. Re-exposure to measles induces a strong anamnestic immune response with a 
rapid boosting of IgG antibodies, preventing clinical disease. Measles virus can be isolated 
from conventional clinical specimens (nasopharyngeal swab, urine or peripheral blood 
mononuclear cells) up to five days following onset of the rash and may be detected using 
polymerase chain reaction (PCR) assays on specimens obtained up to seven days or more 
after onset of the rash. Recommendations for laboratory confirmation of the disease for 
surveillance have been described in the WHO Manual for the laboratory diagnosis of 
measles and rubella virus infection (20). 
 
WHO recommends IgM antibody detection by ELISA as the standard test for routine 
measles surveillance. 
 
In addition to IgM antibody detection, measles can be diagnosed using other methods, 
including a minimum fourfold increase in IgG titre, antigen detection by immunofluorescence, 
reverse transcription (RT) PCR to detect measles virus ribonucleic acid (RNA), or isolation of 
measles virus. False-positive IgM test results may sometimes occur due to cross-reacting 
IgM antibodies to other agents (e.g. Epstein-Barr virus [EBV], human parvovirus B19), 
rheumatoid factor or other auto-antibodies, and polyclonal stimulation of IgM response by 
EBV. 
 
A positive IgM antibody test in recently vaccinated individuals must be interpreted according 
to the clinical signs and the local epidemiology of disease. Mild rash and low-grade fever, 
usually without other symptoms of measles (cough, coryza or conjunctivitis), can be 
observed 1-2 weeks after measles vaccination in some vaccine recipients (10, 13, 21).  
 
In countries with low measles incidence, the use of IgM alone to diagnose a single case of 
measles without evidence of other cases in the community may not be sufficient, and efforts 
should be made to confirm the diagnosis using other laboratory methods in addition to the 
IgM test, and/or to rule out other diseases with similar clinical presentation. 
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2.2 Rubella 
Rubella is an acute viral illness, characterized by mild maculopapular rash often with 
postauricular or suboccipital adenopathy. Usually mild in children, rubella in adults may be 
accompanied by low-grade fever, headache and arthralgias. Less common complications 
are thrombocytopenia and encephalitis (1 per 6000 cases), which may be fatal. Up to 50% of 
infections with the rubella virus can be asymptomatic. Like measles virus, rubella virus is 
also transmitted by respiratory droplets and by direct or indirect contact with the nasal and 
throat secretions of infected persons, but is less contagious. Individuals are most infectious 
when the rash is erupting, but they may shed virus from seven days before to 14 days after 
the onset of rash. Following exposure, the incubation period before onset of symptoms is 
usually 14–18 days (range 12–23 days). The outcome of rubella is most serious when 
infection occurs during early pregnancy, as it can result in spontaneous abortion, stillbirth or 
an infant born with a combination of birth defects, known as CRS (22, 23, 24). 
 
In the pre-vaccine era, the epidemiology of rubella was similar to the epidemiology of 
measles, with seasonal variation and regular epidemic peaks alternating with low-incidence 
periods. In temperate climates, regular seasonal increases of rubella occurred in spring, with 
small epidemics every three to four years, and larger epidemics every six to nine years (22, 
23).  
 
Rubella vaccination programmes have been highly effective in modifying the epidemiology of 
rubella, and a number of countries have eliminated the disease, with a similar effect to that 
of measles vaccination programmes on measles (22, 25). However, in many countries of the 
Region, rubella vaccination has been introduced in different ways and often much later than 
measles vaccination. This has resulted in marked differences in rubella susceptibility profiles 
and rubella epidemiology across these countries. In addition, rubella surveillance is not well 
established in many countries, making estimates of the true burden in Europe difficult. 
 
2.2.1 Laboratory diagnosis of rubella 
 
A number of infections can present with signs and symptoms compatible with rubella. In 
addition, up to 50% of infected persons may have minimal or no clinical symptoms. 
Therefore, a laboratory assessment is critical for confirmation of a clinical rubella diagnosis.  
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Humoral and cell-mediated immunity develop following natural infection and with 
immunization. With natural infection, IgM antibodies become detectable within 3–4 days and 
IgG antibodies within one week of the onset of rash. Rubella-specific IgM can often be 
detected in individuals up to two months after illness and, in a decreasing percentage of 
individuals, up to six or seven months after natural infection, vaccination and reinfection (26). 
In addition, false-positive IgM test results may occur because of cross-reacting IgM 
antibodies (e.g. to EBV, human parvovirus B19, etc.), rheumatoid factor or other auto-
antibodies, and polyclonal immune stimulation by EBV. 
 
Following infection, the virus can be isolated from nasopharyngeal secretions from a few 
days before to up to seven days after the onset of rash. The detection of viral RNA by RT-
PCR may be possible for 3–4 days longer. However, the optimal time to collect specimens is 
within four days of the onset of symptoms (20, 22, 26). 
 
WHO recommends IgM antibody detection by ELISA as the standard test for routine 
rubella surveillance. 
 
In countries with low incidence of rubella, a positive rubella IgM result in a person without 
known exposure to other cases in the community or through travel to endemic countries 
should be assessed using other laboratory methods in order to distinguish a primary rubella 
infection from a false-positive result. Recommendations for testing are described in the WHO 
Manual for the laboratory diagnosis of measles and rubella virus infection (20). 
 
2.2.2 Rubella infections in pregnant women 
 
Cases of rubella in pregnant woman should be reported like any other rubella case and have 
pregnancy status noted on the report form. A single positive IgM test result is sufficient for 
classifying a case as laboratory-confirmed for surveillance purposes. However, for clinical 
management and medical decision-making, additional testing (detection of a significant rise 
of IgG antibodies, avidity testing, rubella immunoblot, virus detection or virus isolation) may 
be needed. A consultation with a medical expert is strongly recommended. Although not 
included in this document, detailed procedures should be in place in all Member States for 
appropriate screening and follow-up of pregnant women exposed to rubella, given the 
serious consequences of rubella infection during pregnancy (27). 
 
Pregnant women known to have been exposed to rubella should be assessed for rubella-
specific IgG antibody and those found to be negative should be monitored for IgM and IgG 
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seroconversion and for the outcome of their pregnancies. Pregnant women found to be 
susceptible should be vaccinated after delivery. 
 
A registry of pregnant women with rubella can be used for recording pregnancy outcomes 
(e.g. abortion, stillbirth, defects associated with congenital rubella) and for laboratory follow-
up of infants (See Chapter 6). 
 
2.3 Congenital rubella syndrome 
 
The most serious consequence of rubella virus infection can develop when a woman 
becomes infected during pregnancy. Infants infected with rubella virus in utero may have a 
variety of physical defects, known collectively as congenital rubella syndrome (CRS). This is 
most likely to develop with maternal infection during the first 12 weeks of pregnancy, 
although isolated birth defects, particularly sensorineural hearing impairment, can be found 
in infants with maternal infection at up to 20 weeks of pregnancy (22). CRS is seen in 0.6–
2.2 children per 1000 live births during epidemics in countries without rubella immunization 
programmes (28). 
 
The clinical features associated with CRS are: ophthalmic (e.g. cataracts, microphthalmia, 
glaucoma, pigmentary retinopathy and chorioretinitis); auditory (e.g. sensorineural hearing 
impairment); cardiac (e.g. patent ductus arteriosus, peripheral pulmonary artery stenosis, or 
ventricular septal defects); and craniofacial (e.g. microcephaly). CRS can also present with 
neonatal manifestations that include meningoencephalitis, hepatosplenomegaly, hepatitis, 
thrombocytopenia and radiolucencies in the long bones (a characteristic radiological pattern 
of CRS). Thrombocytopenia can be fatal. Interstitial pneumonitis is also a complication of 
CRS in infancy (29).  
 
Infants with CRS who survive the neonatal period may face serious disabilities (such as 
visual and hearing impairment) and have an increased risk of developmental delays, type I 
diabetes mellitus and thyroiditis. A progressive rubella panencephalitis, resembling subacute 
sclerosing panencephalitis, has been observed in a few individuals with CRS (22, 30-32).  
 
Infants with congenital rubella infection will have a positive rubella-specific IgM test at or 
shortly after birth, at least through the first three months of life. Because some infants do not 
test positive at birth, a second IgM test should be done shortly after an initial negative result 
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if there is clinical suspicion. Most infants with CRS will be IgM-positive between three and six 
months of life; however, the laboratory confirmation of a possible congenital rubella case in 
an infant aged over six months should not rely on the IgM test alone. In the absence of 
vaccination or postnatal rubella, congenital rubella can also be confirmed by serial IgG 
testing for the sustained presence of IgG over several months.3 All congenitally infected 
infants, including those without clinical manifestations of CRS, may shed virus for up to at 
least one year of age and can transmit rubella to others (27). 
 
2.4 Rationale for disease elimination and 
an integrated approach to measles and 
rubella surveillance in the European 
Region 
Measles and rubella infections have many similarities. Both are viral diseases caused by 
pathogens that infect only humans. In the absence of prevention, both can have a serious 
impact on a population’s morbidity and mortality. Both are also preventable with safe and 
widely used vaccines, which are often given as a combined vaccine. These characteristics 
make elimination of both diseases feasible. 
 
Strategies recommended for elimination of these diseases depend on local epidemiology, 
historical vaccination coverage and the ability of the health system to deliver vaccine with 
high coverage to susceptible groups of people. All Member States currently have routine 
two-dose measles and rubella vaccination programmes using combined vaccines (usually 
measles/mumps/rubella (MMR) vaccine). Many countries that have recently introduced 
rubella vaccine have also undertaken supplementary immunization activities using combined 
measles and rubella (MR) vaccine with a strategy targeting susceptible children, adolescents 
and women of childbearing age, or in some cases adults of both sexes. 
 
Integrating rubella and measles surveillance is cost-effective, given that the symptoms of the 
diseases are similar and both diseases commonly affect the same age groups. Thus, testing 
of specimens of suspected measles or rubella cases (at least IgM-negative ones) for the 
                                                          
3
 Maternal IgG will be declining or absent after six months of age. 
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other disease is clinically and epidemiologically sound as it allows to confirm or rule out each 
of two diseases. 
 
As the incidence of measles and rubella declines, Member States will need to ensure that their 
surveillance systems remain sensitive to the detection of sporadic cases. Based on the 
experience of countries that have eliminated measles, the principal benchmark for assessing 
the quality of surveillance in the absence of, or at low incidence of, measles and/or rubella is 
the rate of suspected cases which have been investigated and discarded. The rate of 
discarded cases should be at least 2 per 100 000 population per year at the national level, and 
in >80% subnational administrative units (additional details are given in Chapter 5).  
 
Achieving this benchmark requires that all sporadic illnesses clinically consistent with measles 
or rubella be thoroughly investigated and adequate specimens obtained for laboratory 
confirmation and, if possible, virus isolation. If serum specimens have not been obtained, or 
were collected outside the time period optimal for IgM detection, other tests or types of 
specimens should be used to determine etiology. In the absence of laboratory results, cases 
clinically consistent with measles or rubella which cannot be epidemiologically linked to other 
confirmed cases should be classified as clinically compatible cases and reported to the 
surveillance system. In countries with an annual incidence of measles or rubella of <1 per 
1 000 000 population, all cases should be either laboratory-confirmed or epidemiologically 
linked to a laboratory-confirmed case. 
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3 Case definitions for 
surveillance and reporting of 
measles and rubella 
 
Surveillance systems use case definitions designed to standardize reporting across health 
facilities and at various levels of the health system – subnational, national and international. 
This facilitates aggregation, analysis and interpretation of data, as well as a comparison 
between geographical areas and over time. These definitions are for surveillance purposes 
and do not replace clinical diagnosis. The case definitions for measles and rubella include the 
following categories: suspected, laboratory confirmed, epidemiologically linked, clinically 
compatible and discarded cases.  
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3.1 Measles 
The clinical criteria for measles are:  
 fever and  
 maculopapular rash (i.e. non-vesicular rash) and  
 cough or coryza (runny nose) or conjunctivitis (red eyes).  
 
The laboratory criteria for measles surveillance case confirmation are: 
 measles IgM antibody detection or  
 measles virus isolation or  
 measles viral RNA detection by RT-PCR or  
 a significant rise in measles IgG antibody in paired sera.  
 
Box 1 sets out the case classifications for surveillance for measles. 
 
Box 1 
Measles case definitions for surveillance purposes 
Case category Definition  
Suspected A case with signs and symptoms consistent with clinical criteria of 
measles. 
All suspected cases have to be investigated and classified based on clinical, laboratory and 
epidemiological data as one of the following: 
Laboratory 
confirmed  
A suspected case which meets the laboratory criteria for measles 
case confirmation. 
 
Epidemiologically 
linked 
A suspected case which has not been adequately tested by laboratory 
and which was in contact with a laboratory-confirmed measles case 
7–18 days before the onset of rash. 
  
Clinically 
compatible 
A suspected case which has not been adequately tested by laboratory 
and has not been epidemiologically linked to a confirmed measles 
case. 
 
Discarded A suspected case which was investigated and discarded, either 
through negative results of adequate laboratory testing for measles or 
by an epidemiological link to a laboratory-confirmed case of another 
disease.  
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3.2 Rubella 
The clinical criteria for rubella are: 
 maculopapular rash and 
 cervical, suboccipital or postauricular adenopathy, or arthralgia/arthritis. 
 
The laboratory criteria for rubella surveillance case confirmation are: 
 rubella IgM antibody detection or 
 rubella virus isolation or 
 rubella viral RNA detection by RT-PCR or 
 a significant rise in rubella IgG antibody in paired sera. 
 
Box 2 sets out the case classifications for surveillance for rubella. 
 
 
Box 2 
Rubella case definitions for surveillance purposes 
Case category Definition  
Suspected A case with signs and symptoms consistent with rubella clinical 
criteria.  
All suspected cases have to be investigated and classified based on clinical, laboratory and 
epidemiological data as one of the following: 
Laboratory 
confirmed  
A suspected case which meets the laboratory criteria for rubella case 
confirmation. 
 
Epidemiologically 
linked 
A suspected case which has not been adequately tested by laboratory 
and which was in contact with a laboratory confirmed rubella case 12–
23 days before the onset of symptoms.  
 
Clinically 
compatible 
A suspected case which has not been adequately tested by laboratory 
and has not been epidemiologically linked to a confirmed rubella case. 
 
Discarded A suspected case which was investigated and discarded, either 
through negative results of adequate laboratory testing for rubella or 
by an epidemiological link to a laboratory-confirmed case of another 
disease.  
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A case-classification flowchart for measles and rubella surveillance is shown in Fig. 1. 
 
Fig. 1. Case classification algorithm for measles and rubella* 
 
* For operational approach to interpreting positive measles and rubella IgM results in special 
circumstances, see Box 3. 
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Box 3 
Operational approach to interpreting measles and rubella IgM results in special 
circumstances 
 
 
 
 Specimen taken early after rash onset 
In case of negative IgM result in a serum sample taken earlier than four days after onset 
of the rash, a second sample should be taken between four and 28 days following onset 
of the rash. If obtaining the second sample is not feasible, the case should be classified 
based on the results of the available sample. 
 
 Indeterminate results 
Specimens with indeterminate IgM results should be retested. If the test result remains 
indeterminate following repeat testing, the sample may be tested by an alternate method 
or another sample obtained and tested. If the results continue to remain indeterminate, or 
additional testing is not feasible, the case should be classified based on the presence of 
an epidemiological link to another laboratory-confirmed case.  
 
 Results in recent vaccine recipients 
Recent recipients of measles and/or rubella vaccine are expected to have detectable IgM 
for the respective antigens. Serological techniques cannot distinguish between immune 
responses to natural infection and immunization; only genetic characterization of the virus 
can help distinguish an IgM response to natural infection from the one induced by the 
vaccine. Suspected cases with virus characterization performed in which only vaccine, 
but not wildvirus is detected, should be classified as “discarded”. 
 
An operational approach to classification of suspected cases with an IgM-positive result 
which have a recent history of vaccination but in which virus characterization has not 
been performed, is as follows (10, 20).  
 
Generally, any suspected case with positive IgM result, including recent vaccine 
recipients, should be considered laboratory-confirmed, EXCEPT cases which meet ALL of 
the criteria listed below. These cases should be discarded. 
 
The criteria for discarding IgM-positive cases in recent vaccine recipients: 
 history of vaccination with relevant vaccine seven days to six weeks prior to 
specimen collection; 
 rash onset 7-14 days after vaccination; 
 active search in community does not reveal evidence of virus transmission;  
 no history of travel to areas where the virus is known to be circulating. 
 
The same algorithm applies to recently vaccinated cases with other serological evidence 
of acute infection (i.e. significant increase in IgG antibodies). 
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3.3 Classification of cases by origin of 
infection 
As countries approach measles or rubella elimination, cases should be classified both 
according to the case-confirmation status (i.e. laboratory confirmed, epidemiologically linked, 
or clinically compatible) and origin of infection (i.e. endemic, imported, import-related or of 
unknown origin). The definitions and classification of measles and rubella cases by their 
origin are shown in Box 4. 
 
Box 4 
Case definitions for measles or rubella cases by their origin 
Case category Definition 
Endemic A case resulting from endemic transmission of the virus (i.e. 
virus present at the territory for ≥12 months) as confirmed by 
laboratory testing or epidemiological linkage.  
 
Imported A case with virological or epidemiological evidence, or both, 
of exposure outside the region or country during the 7–18 
days (for measles) or 12-23 days (for rubella) prior to rash 
onset. 
 
Import-related A case with locally acquired infection but caused by imported 
virus, as supported by epidemiological or virological 
evidence, or both. The index case for this infection/chain of 
transmission is an imported case. If virus transmission 
related to importation persists for ≥12 months, cases are no 
longer considered to be import-related, but endemic. 
 
Unknown origin of 
infection 
A case where the origin of infection cannot be determined. 
There may be objective reasons making classification into 
one of the above categories impossible, but cases of 
unknown origin may also be indicative of endemic 
transmission missed because of suboptimal performance of 
the surveillance system. 
 
Surveillance Guidelines for Measles, Rubella and Congenital Rubella Syndrome in the WHO European Region  
Update December 2012 
Case definitions for surveillance and reporting of measles and rubella  22 
 
To make this classification possible, national surveillance systems must have reliable 
epidemiological and virological data on measles and rubella for a minimum period of 
12 months, with a comprehensive database of virus genotypes. 
 
The following table illustrates the 12 possible classification categories for every measles or 
rubella case in low-incidence settings. 
 
Table 1 
Classification of measles or rubella cases, by confirmation status and origin of 
infection 
Origin of 
infection 
Case classification 
Laboratory-
confirmed 
Epidemiologically linked Clinically 
compatible 
Endemic  a b c 
Imported d e f 
Import-related g h i 
Unknown j k l 
 
3.4 Measles and rubella outbreaks 
 
In countries with elimination goals, outbreaks of measles and rubella are defined as follows. 
 
 Measles outbreak – two or more confirmed cases which are temporally related (with 
onset of rash in cases occurring between 7 and 18 days after exposure), and 
epidemiologically or virologically linked, or both. 
 
 Rubella outbreak – two or more confirmed cases which are temporally related (with 
onset of rash in cases occurring between 12 and 46 after exposure), and 
epidemiologically or virologically linked, or both.4 
 
In populations with very high immunity (natural or due to immunization), virus transmission 
after importation is usually self-limited and results in sporadic cases or small 
clusters/outbreaks which are resolved without intervention. However, virus introduction into 
                                                          
4
 The timeframe includes two incubation periods owing to the frequency of subclinical rubella 
infections. 
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pockets of susceptibles or in population groups with large numbers of susceptibles may 
result in large-scale, sometimes nationwide, outbreaks.  
 
Outbreaks should be investigated so that their extent and origin can be determined. This 
information will lead to a better understanding of their epidemiology and help with defining 
and tailoring interventions in order to decrease the size of susceptible populations and 
control the outbreaks. 
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4 Measles and rubella 
surveillance 
 
Public health surveillance requires prompt dissemination of information to those who need it 
so that appropriate action can be taken at each level of the health system. It is critical that 
surveillance and response occur at national and subnational levels. In the case of diseases 
where the target is elimination, it is also critical that reporting, response and feedback also 
take place at the international level through:  
 
 prompt communication of data, information and reports between Member States and 
WHO, European-Union-related institutions and other European networks; and 
 provision of samples/strains/sequence data to WHO reference laboratories. 
 
The general logistics of surveillance are presented and discussed in Making surveillance 
work. Module 3: logistics management (33). 
 
With the goal of eliminating measles and rubella in the WHO European Region, it is critical 
that all countries should implement case-based surveillance to detect, investigate and 
confirm every suspected measles and rubella case in the community. Comprehensive 
nationwide surveillance systems based on standardized case definitions are essential to 
ensure that all necessary information on individual cases is collected and reported through 
collaboration by clinicians, epidemiologists and virologists. The information sufficient for 
monitoring progress and documentation for achieving elimination can be obtained only 
through case-based surveillance, which implies reporting of individual cases rather than 
reporting aggregated numbers. 
 
National health authorities and technical experts should create protocols for measles and 
rubella surveillance and case investigation most appropriate for their health system. This 
protocol should define roles of health institutions and different technical experts in 
investigation of measles cases, together with standard operating procedures. The regional 
guidelines should be used as a background document for establishing the surveillance 
system, as this will assure collection of uniform critical information in all Member States, 
harmonization of surveillance and response activities, and comparison and analysis of data 
at the regional level. 
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Investigation of measles and rubella cases begins with a clinician who suspects measles or 
rubella in a patient with relevant clinical manifestations and notifies the public health 
authorities. Under case-based surveillance, epidemiological investigation including 
laboratory testing should be conducted for all suspected cases of measles and rubella 
immediately upon notification. The following practical steps should be part of the case 
investigation: 
 
 A unique identifier (or EPID number) should be assigned to each case (e.g. country 
code + district code + year + sequential number by order of reporting), to facilitate 
further collection and merging of clinical, epidemiological and laboratory data. In 
many systems, the identifier is created by the epidemiology unit after notification. 
 Accurate relevant information should be obtained from the case (or the family if 
necessary), including demographic and clinical information, vaccination status, 
pregnancy status and travel history. This is usually the responsibility of clinicians and 
epidemiologists. Availability of accurate and timely information will decrease time 
needed for investigation and help with laboratory investigation. 
 An attempt should be made to identify the source of infection for a case (contact with 
possible infectious measles or rubella cases, travel in an epidemic area, etc.) and 
active search for other cases in the area should be carried out. 
 Outbreaks should be adequately investigated and documented. Every outbreak 
should have a unique identifier and all cases from the same outbreak should be 
coded accordingly. Adequate clinical and epidemiological investigation linking a 
particular case with an outbreak will decrease the work burden on laboratories. 
 As laboratory results are critical for case classification, specimens should be 
collected for confirmation and virus isolation/detection. This is recommended as a 
step in the clinician’s work during the first (and maybe only) contact with the patient, 
or as soon as feasible. 
 The investigation form should be completed to collect data for further analysis (an 
example of a form and a list of variables to collect are given in Annexes 1 and 2). 
Since information will be collected by different institutions and will become available 
at different times (e.g. laboratory results later than immunization status), it is 
important to ensure that all participants know which information they have to collect 
and to whom it should be transmitted. 
 Case investigation should include identification of contacts exposed to the case when 
he/she was infectious, and their family members. They should be interviewed to 
check their vaccination status, provide appropriate information, encourage them to 
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consult a clinician if symptoms consistent with measles or rubella appear, and 
provide appropriate public health interventions, potentially including vaccination. 
 
4.1 Laboratory assessment algorithms for 
measles and rubella infection 
Laboratory investigation has a critical role in measles and rubella elimination because of the 
unreliability of clinical characteristics of these diseases for accurate diagnosis and the need 
to distinguish endemic and imported viruses. In order to enhance the cost–effectiveness of 
integrated surveillance for measles and rubella, laboratory assessment should be based on 
the epidemiology of measles and rubella in the country, and the clinical and epidemiological 
information on the case. 
 
The following algorithm is proposed for testing of suspected cases of measles and rubella: 
 
 In countries with high incidence of both measles and rubella: 
- test specimen for measles first 
- if negative, test for rubella. 
 In countries with low incidence of measles and high incidence of rubella: 
- test specimen for rubella first 
- if negative, test for measles. 
 In countries with low incidence of both measles and rubella: 
- test specimens for both infections. 
 
 
4.1.1 Collection of samples for measles and rubella testing 
The correct timing for the collection of samples is vital for obtaining an adequate sample and 
interpreting the test results. The diagnostic tests used to confirm measles and rubella 
infection include both antibody and antigen detection, but the timing of sample collection will 
determine which tests can be conducted (Table 2). The typical sample for disease 
confirmation is serum, but alternative specimen types (oral fluid, dried blood spots, etc.) are 
increasingly used in some countries. Details of the collection, storage and shipment of 
specimens are provided in the WHO manual for the laboratory diagnosis of measles and 
rubella virus infection (20) and in Annex 3. 
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Table 2  
Clinical samples for measles and rubella collection and recommended time* of collection 
 
*Time measured in days after the onset of rash. 
 
4.1.2 Antibody detection 
A single sample (e.g. serum) obtained at the first contact with the health-care system 
at any time within 28 days after onset is considered adequate for surveillance purposes. 
Because of the higher proportion of false-negative results found in specimens collected 
within 72 hours of onset of the rash, in a serum sample taken earlier than four days after 
onset of the rash which has a negative IgM result, a second sample should be taken 
between four and 28 days following onset of the rash. If the second specimen has not 
been obtained, case classification should be based on the results of testing the single 
specimen. 
 
4.1.3 Virus isolation 
In contrast to antibody detection, virus isolation is most successful when clinical specimens 
are collected during the first four days following onset of the rash. Virus can be isolated from 
nasopharyngeal secretions, oral fluid samples, urine and whole blood collected as soon as 
possible after the appearance of the rash. Measles and rubella viruses are sensitive to heat, 
and detection decreases markedly when specimens are not kept cold (4–8oC). It is important 
that samples are transported under cold conditions as soon as possible following collection. 
Clinical samples Assays
0–4 days 5–7 days 8–28 days
Serum/dry blood 
spots
IgM/IgG   
Virus detection   
Whole blood
Virus isolation   
Virus detection   
Nasopharyngeal 
secretions
Virus isolation   
Virus detection   
Urine
Virus isolation   
Virus detection   
Oral fluid
IgM/IgG   
Virus isolation   
Virus detection   
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4.1.4 Reverse transcription PCR 
Measles and rubella viruses can be detected by PCR in nasopharyngeal secretions, urine, 
serum and whole blood, and dry blood spots up to seven days after onset of the rash and in 
oral fluid for even longer.  
 
4.1.5 Laboratory testing during outbreaks 
In outbreak settings, it is recommended that specimens from 5–10 cases early in the 
outbreak are submitted for laboratory testing. Once the outbreak is confirmed as measles 
or rubella, subsequent cases should be primarily confirmed based on epidemiological 
linkage. If the outbreak continues, an additional 5–10 specimens should be submitted to 
the laboratory every two to three months to confirm that the illness in question is still 
measles or rubella and to monitor the implicated virus genotype(s). An important exception 
to this rule is a case of suspected measles or rubella in a pregnant woman, when 
laboratory testing should be performed regardless of the background incidence.  During 
outbreaks, cases should be reported to WHO using both the case-based reporting form 
and the outbreak aggregate reporting form (see Annexes 1 and 4 for examples of data 
collection forms). 
 
4.2 Data collection and reporting 
Public health authorities at all levels should establish a well functioning surveillance network 
that meets the reporting requirements of the elimination stage of measles and rubella. The 
case notification form or set of core information should be transmitted by the clinician to the 
local epidemiologist. The notification and investigation information should then be 
transmitted from local levels to higher administrative levels of the surveillance system, 
including to the national level. Each administrative health subdivision within a country should 
be part of the reporting system. The following approach for data transmission can be 
recommended, based on the incidence of disease in the country: 
 
 Case-based data should be collected at the primary level of the system (see Annex 1 
for example of case investigation form). 
 Case-based data on all suspected cases that have been investigated and classified, 
including cases classified as discarded, should be reported from local up to national 
level, to allow for adequate epidemiological analysis. A line listing of cases (database 
with all relevant information) in the area under surveillance should be available at all 
levels of the system.  
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 All sporadic cases and disease clusters should be reported immediately upon 
detection, and subsequently to all surveillance levels according to national 
regulations. During an outbreak, reporting should be weekly after the initial report. If 
timely case-based reporting during an outbreak is not feasible because of the large 
number of cases, case-based data should still be collected and entered into the 
database as soon as it becomes feasible. 
 Monthly zero reporting (i.e. reporting even if there are no cases) should be 
implemented at all levels of the system, in order to monitor quality of surveillance. 
 
Laboratories should confirm sporadic cases by IgM testing within three days of receiving the 
specimens. Weekly surveillance reports are recommended when transmission is ongoing 
followed by weekly zero reporting after an outbreak for at least two incubation periods. 
 
Feedback should be provided with similar regularity to data reporting. Comprehensive 
reports which include an epidemiological description, and implemented activities and 
recommendations for control, should be compiled at the end of an outbreak. The regional 
outbreak investigation and reporting form (see Annex 4) may be adapted for reporting 
purposes in the national health system. 
 
The quality of data collected in the process of an outbreak investigation is critical for 
determining the control strategy and activities. With adequate investigation of outbreaks, the 
surveillance system will have information about susceptible populations and explanations for 
their susceptibility.  
 
The size and duration of outbreaks may be used by national surveillance systems as an 
indirect indicator of immunity, immunization coverage, quality of surveillance system and 
adequacy of response and control measures. However, without a thorough outbreak 
investigation that includes active case-finding and epidemiological linkage of cases, these 
data can be misleading. 
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4.3 Reporting to WHO 
The objectives of reporting to WHO are to: 
 
 provide a standardized, up-to-date and complete picture of the epidemiology of 
measles and rubella in the Region, to indicate the burden they place on public health 
and facilitate response and control measures; 
 identify more precisely the geographical areas and populations where particular 
problems are occurring and action is needed (subnational level or geographical area 
with specific risk, risk groups by age and gender); 
 ensure timely dissemination of critical and accurate information about infectious 
diseases among public health professionals. 
 
Member States have technical staff in national health institutions designated as the WHO 
counterparts for measles and rubella surveillance, with a responsibility to provide national 
surveillance data for the Regional Office through the Centralized Information System for 
Infectious Diseases (CISID5) or sending reports via other means. 
 
Member States should report routine measles and rubella case-based surveillance data 
monthly to WHO. Complete and accurate data from all suspected cases, including 
confirmed, epidemiologically linked and clinically compatible cases and discarded cases, 
should be provided. In the absence of disease, countries should provide monthly zero 
reports. Countries belonging to the European Union send their notifications through the 
European Centre for Disease Prevention and Control, which transmits these data on a 
monthly basis to the Regional Office. 
 
Real-time case-based reporting in the national surveillance systems (such as Web-based 
reporting) allows real-time surveillance of diseases. If cases are properly coded, information 
about clustering of cases and confirmed outbreaks with all related cases will be immediately 
available. As real-time reporting is not possible at the regional level (because of the delay in 
data availability due to monthly reporting), the Regional Office recommends reporting of 
outbreaks using the form presented in Annex 4. It is expected that surveillance counterparts 
will send this form twice, at the beginning of the outbreak as a notification form, and at its 
end as a final report form. 
 
                                                          
5
 http://data.euro.who.int/cisid/, accessed 15 December 2012.  
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5 Monitoring and evaluation 
 
Monitoring and evaluation of surveillance systems over time is necessary to identify areas 
that need strengthening and to verify the relevance and quality of the information obtained. 
These objectives are particularly important in the context of eliminating measles and rubella. 
 
To help with the routine monitoring of surveillance systems, WHO has defined a set of core 
indicators for measles and rubella (see Chapter 5.1 “Surveillance performance indicators” 
below). Together with surveillance indicators, indicators for monitoring progress towards 
elimination are helpful in determining the current status and activities needed for elimination 
(see Chapter 5.2 “Indicators for monitoring progress towards elimination” below). 
 
Surveillance performance should be analysed at each administrative level in order to monitor 
and document local and national progress towards achieving and sustaining elimination. 
Indicators for monitoring progress must be interpreted with regard to the quality of disease 
surveillance and also with regard to the immunity profile of specific subgroups (age group, 
geographical area, etc.) when available.  
 
In addition to routine monitoring, detailed periodic reviews of system performance should be 
conducted with reasonable frequency (between annually and every five years) to assess 
system quality and implement modifications based on the review findings. 
 
5.1 Surveillance performance indicators 
The following indicators (Table 3) measure the performance of measles and rubella 
surveillance.
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Table 3 Measles and rubella surveillance performance indicators 
 
Indicator Description Target 
Timeliness of 
reporting  
The number of measles and rubella routine reports 
submitted before a deadline, divided by the number 
of reports expected in the reporting month or year 
 100%  
≥80% of reports received before a deadline 
 
 
Completeness of 
reporting  
The number of measles and rubella routine reports 
submitted, divided by the number of reports 
expected in the reporting month or year x 100%  
≥80% of reports received  
Laboratory 
investigation rate 
The number of cases with specimens adequate for 
detecting1 measles or rubella collected and tested 
in a proficient laboratory2 divided by the number of 
suspected cases × 100%. 
 
Specimens adequate for detecting acute 
measles/rubella infection should be 
collected and tested in a proficient 
laboratory from ≥80% of suspected 
measles/rubella cases. Any suspected cases 
that are not tested by the laboratory and are 
a) confirmed by epidemiologic linkage or b) 
discarded as non-measles/non-rubella by 
epidemiological-linkage to a laboratory-
confirmed case of another communicable 
disease or epidemiological-linkage to a 
measles or rubella IgM-negative case, should 
be excluded from the denominator. 
Rate of discarded 
cases 
The rate of suspected measles or rubella cases that 
have been investigated and discarded as non-
measles or non-rubella cases using laboratory 
testing in a proficient laboratory and/or 
epidemiological linkage to another confirmed 
disease 
 
At least 2 discarded measles/rubella cases 
should be reported annually per 100,000 
population nationwide and in ≥80% of 
subnational administrative units (e.g. at the 
province level or its administrative 
equivalent)  
Chains of 
transmission/out
breaks 
investigated for 
virus genotype 
The number of measles or rubella chains of 
transmission/outbreaks investigated for virus’ 
genotype, divided by the number of laboratory-
confirmed chains of transmission/outbreaks of that 
disease  100% 
 
Samples adequate for virus detection should 
be collected from ≥80% of laboratory-
confirmed chains of transmission/outbreaks 
and tested in WHO accredited laboratory.  
Origin of 
infection  
The number of measles or rubella cases for which 
an origin of infection is identified (e.g. imported, 
import-related, or endemic), divided by the total 
number of cases reported  100%. 
≥80% of cases with identified origin of 
infection  
Timeliness of 
investigation 
The number of suspected measles or rubella cases 
with an adequate investigation3 initiated within 48 
hours of notification divided by the total number of 
suspected cases reported  100% 
At least 80% of all reported suspected 
measles/rubella cases should have had an 
adequate investigation initiated within 48 
hours of notification.  
1 See Chapter 4.1 and Annex 3 for instructions 
2 A proficient laboratory is a laboratory that uses a validated assay and participates in the laboratory quality assurance programme of 
the WHO Global Measles and Rubella Laboratory Network (14).  
3 An adequate investigation includes collection of all of the following data elements from each suspected measles/rubella case: case 
identifier, age (or date of birth), sex, date of rash onset, date of specimen collection, vaccination status, date of last vaccination, travel 
history and contacts. 
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5.2 Indicators for monitoring progress 
towards elimination 
Vaccination coverage and disease incidence are useful indicators for providing general 
guidance regarding progress towards elimination. However, they are not sufficient to 
document elimination by themselves. Rather, an assessment of several lines of evidence 
(e.g. population immunity, quality of surveillance, molecular epidemiology data, etc.) will be 
necessary for reliable conclusions to be drawn. In countries with small populations, these 
indicators should be interpreted with caution. 
 
1. Vaccination coverage 
Countries should monitor vaccination coverage continuously to enable population 
immunity to be assessed. Although high coverage with one dose of the rubella-
containing vaccine provides sufficient protection against rubella and is likely to interrupt 
transmission, all Member States of the European Region have currently implemented a 
routine immunization programme offering two doses of combined measles and rubella-
containing vaccines (MR, MMR, measles/ mumps/ rubella/ varicella – MMRV). 
Indicator: 
Vaccination coverage of the first and second routine doses of measles/rubella-
containing vaccine. 
Target: 
Achieving and maintaining of at least 95% coverage with both first and second routine 
doses of measles/rubella-containing vaccine in all districts or their administrative 
equivalents and at the national level. 
 
2. Incidence 
Incidence of measles or rubella is a basic measure of progress in disease elimination, 
used to describe the overall level of disease control and enable meaningful 
comparisons across countries and regions. Monitoring incidence is reliable only when 
the surveillance system meets essential performance indicators.  
Indicator: 
Incidence of ALL measles or rubella (laboratory confirmed, epidemiologically linked and 
clinically compatible) cases per million total population. The numerator should exclude 
imported cases. 
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Target: 
Achievement of a measles/rubella incidence of <1 case per 1 million total population. 
 
Meeting individual indicators for monitoring progress towards elimination does not define 
measles elimination nor confirm that it has been achieved. Conclusions regarding verification 
of measles and rubella elimination should be based on examination of several lines of 
evidence.
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6 Surveillance of CRS 
6.1 Rationale 
 
The public health justifications for congenital rubella surveillance are to monitor the 
effectiveness of rubella vaccination programmes, to detect and isolate affected infants 
rapidly, and to mitigate the consequences of the disease for infants and their families 
through early provision of appropriate medical care. CRS surveillance allows for detection of 
infants with clinically apparent manifestations and can be standardized for regional and 
global reporting and comparison purposes. All Member States should develop a CRS 
surveillance system that captures the majority of infants with suspected CRS within the 
country. If there is no surveillance in place, countries may opt to establish CRS surveillance 
in a few sentinel sites first, then to broaden the surveillance and add additional sites to 
include more of the population. 
 
Rapid identification of infants with CRS is necessary to ensure that appropriate testing can 
be conducted and the infant entered into the CRS surveillance system. Detection of infants 
with CRS is necessary to ensure infection control and prevent further spread of rubella, as 
infants with CRS may shed virus for prolonged period, up to one year of age or longer. 
Immediate diagnosis of CRS also facilitates early intervention for specific defects.  
 
This section has been developed to provide a comprehensive framework for developing and 
monitoring high-quality CRS surveillance. 
 
6.2 CRS – clinical features, case 
classification and laboratory criteria for 
confirmation 
 
Classification of cases for CRS surveillance purposes is based on clinical, epidemiological 
and laboratory data. The case definitions for CRS surveillance include the following 
categories: suspected, laboratory confirmed, clinically compatible, epidemiologically linked 
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and discarded. The case definitions for CRS surveillance purposes are given in Box 5. The 
algorithm for classification of suspected CRS cases is presented in Fig. 2. 
 
The clinical criteria for CRS include the presence of >2 clinical features from group A, or one 
feature from group A and >1 from group B in the following list: 
 
Group A  
Sensorineural hearing impairment 
Congenital heart disease 
Pigmentary retinopathy 
Cataract(s) 
Congenital glaucoma 
 
Group B 
Purpura 
Splenomegaly 
Microcephaly 
Developmental delay 
Meningoencephalitits 
Radiolucent bone disease 
Jaundice with onset within 24 hours of birth 
 
Laboratory criteria for confirmation of suspected CRS cases include the following: 
 Rubella IgM antibody detected, or 
 Sustained rubella IgG antibody level as determined on at least two occasions 
between 6 and 12 months of age in the absence of receipt of rubella vaccine; or 
 Rubella virus detection (e.g. nucleic acid detection by RT-PCR or rubella virus 
isolation) in an appropriate clinical sample (best results come from throat swabs, but 
nasal swabs, blood, urine, or cerebrospinal fluid specimens are also acceptable). 
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Box 5 
CRS case definitions for surveillance purposes 
 
Case category Definition  
Suspected Any infant aged <1 year with >1 clinical features from group A and 
no other obvious cause 
All suspected cases have to be investigated and classified based on clinical, laboratory and 
epidemiological data as one of the following: 
Laboratory confirmed  A suspected case which meets the laboratory criteria for CRS case 
confirmation 
 
Clinically compatible  A suspected case which meets the clinical criteria for CRS and 
has not been adequately tested by laboratory  
 
Epidemiologically 
linked 
A suspected case which does not meet clinical criteria for CRS 
(i.e. has only one feature from group A), has not been adequately 
tested and has maternal history of laboratory-confirmed rubella 
during pregnancy 
 
Discarded A suspected case with negative results of adequate laboratory 
testing for evidence of rubella virus infection, or a suspected case 
which does not meet clinical criteria for CRS (i.e. has only one 
feature from group A), has not been adequately tested, and does 
not have maternal history of laboratory-confirmed rubella during 
pregnancy 
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Fig. 2. Classification algorithm for CRS cases 
 
 
Efforts should be made to obtain clinical specimens for viral isolation from infants at the time 
of the initial investigation. Infants with congenital rubella, even without clinical features of 
CRS, will usually be positive for rubella-specific IgM at or shortly after birth. Although IgM 
antibodies may persist for up to one year, they normally peak within the first six months of 
life. Because IgM may not be detectable in some infants tested shortly after birth, IgM-
negative infants with suspected CRS should be retested at one month of age or shortly 
thereafter. Laboratory confirmation of CRS in an infant aged over six months should not rely 
on the IgM test alone if the result is negative. In such cases, serial IgG testing should also be 
performed to assess for a sustained level of antibody over several months. Infants with 
congenital rubella should also be tested for shedding of rubella virus through virus isolation 
techniques. Congenitally infected infants may shed and transmit rubella virus for up to one 
year of age and be the source of rubella outbreaks (27). Therefore, it is important to continue 
testing the infant for virus throughout the first year of life so that infection control measures 
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can continue until virus shedding stops. This has to be confirmed by two negative results of 
viral testing of specimens obtained one month apart from infants at least three months of 
age. 
 
Member States are encouraged to report all clinically compatible, laboratory confirmed and 
epidemiologically linked cases of CRS to the WHO Regional Office. A standard reporting 
form should be completed for each suspected case of CRS (see Annex 5). 
 
6.3 CRS surveillance 
All Member States of the WHO European Region need a CRS surveillance system that has 
the ability to capture the majority of infants with suspected CRS within the country. Routine 
surveillance for CRS should focus on identifying infants under one year of age, although 
some defects associated with CRS surveillance may not be detectable until an older age 
(34). The most common congenital defects related to CRS – cataracts, heart defects and 
hearing impairment – are the primary conditions under CRS surveillance. These conditions 
are most likely to be seen at secondary and tertiary health-care facilities, which should be 
included as sentinel sites for CRS surveillance.  
 
National health authorities should define the objectives and overall structure of the CRS 
surveillance system, which should be aligned with the existing communicable-disease 
surveillance system, health-care structure and capacities. The process may vary depending 
on differences between national health systems, but in most Member States CRS 
surveillance will be integrated into existing surveillance of vaccine-preventable diseases and 
into measles and rubella elimination activities. Member States should report CRS cases to 
WHO according to national surveillance system capacities, at least annually. 
 
The following steps, discussed in more detail in Annex 6, should be implemented to 
establish CRS surveillance (34). 
 
1. Identify national CRS surveillance coordinators responsible for epidemiological 
and laboratory components of the system. 
2. Determine the health-care facilities at which infants with CRS are likely to be 
seen and enrol these facilities as sentinel surveillance sites; identify a CRS 
surveillance coordinator at each facility or group of facilities. 
3. Conduct initial and refresher training for participating providers. 
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4. Initiate CRS surveillance activities. 
5. Conduct quality assessment and monitoring of CRS surveillance. 
6. Expand CRS surveillance and include other sites, as appropriate. 
7. Analyse CRS surveillance data on an annual basis, or more frequently if 
necessary. 
8. Provide periodic feedback to all stakeholders involved in the CRS surveillance 
system. 
 
CRS surveillance that identifies the majority of infants with suspected CRS in a Member 
State is optimal for documentation of the elimination process. This does not mean that all 
health-care providers/institutions must participate in surveillance. Participation of the sentinel 
secondary and tertiary care facilities most likely to treat infants with eye, ear and heart 
defects, is sufficient.  
 
6.4 Other approaches to identifying CRS 
cases 
6.4.1 Rubella in pregnancy registries 
Rubella in pregnancy registration can be used for follow-up of pregnant women exposed to 
rubella and their pregnancy outcome(s), as well as for identification of CRS cases. Rubella in 
pregnancy registries should be maintained at the local level so that comprehensive follow-up 
of pregnant women can occur, and if applicable, infants born with CRS can be identified and 
diagnosed immediately and obtain early interventions for any associated defects. The 
registry should include maternal contact data and demographic data, disease case 
classification for the pregnant women (laboratory confirmed, clinically compatible or 
epidemiologically linked) and pregnancy outcome (e.g. miscarriage, termination, infant with 
CRS, etc.).  
 
6.4.2 Retrospective searches for CRS cases 
Retrospective searches allow for a rapid identification of infants with CRS by reviewing 
medical records of infants with defects or signs consistent with CRS. Retrospective searches 
can help determine a baseline for the burden of CRS in a country. However, one limitation of 
this approach is that retrospectively identified cases usually do not have laboratory 
confirmation. Several studies on conducting retrospective searches for CRS cases are 
available as possible models (35-37). 
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Annex I Integrated measles and rubella case 
investigation form 
    Recommended basic set of data for case-based reporting in national surveillance system 
Case ID:     Region:       District:      
Date of notification: / /   Date of investigation: / /   Date of report: / /   
Initial clinical diagnosis: 1. Clinical measles  2. Clinical rubella  3. Others  9. Unknown  
Outbreak-related: 1. Yes    2. No  9. Unknown   Outbreak ID:      
 
A. Personal data and immunization status 
Name*: ______*WHO Europe does not collect this information – please provide only Case ID number ____ 
Sex: 1. Male    2. Female   9. Unknown  
Date of birth:  /___/  if not available, age in years ____or for younger than a year, age in months_____    
Address*: ______*WHO Europe does not collect this information                ____ 
 
For female cases 
Is case pregnant? 1. Yes  2. No  If yes, gestation age: weeks 
Vaccination status 
Measles: 1. Yes  2. No  3. Unknown  If yes, no. of doses  Last vaccination date:  
Source of vaccination status: 1. Medical record  2. Parent or guardian   / /   
 
Rubella: 1. Yes  2. No  3. Unknown  If yes, no. of doses  Last vaccination date: 
Source of vaccination status: 1. Medical record  2. Parent or guardian   / /   
 
B. Clinical information 
 
Maculopapular rash 1. Yes  2. No   9. Unknown  
Date of rash onset: ______/_____/____  Duration of rash (days):  _________ 
Other symptoms 
Presence of 
complications 
Yes  No  
Fever Yes  No  Unknown    Pneumonia Yes  No  Unknown  
Coryza Yes  No  Unknown   Malnutrition Yes  No  Unknown  
Cough Yes  No  Unknown   Diarrhoea Yes  No  Unknown  
Conjunctivitis Yes  No  Unknown   Encephalitis Yes  No  Unknown  
Adenopathy or arthralgia 
or arthritis 
Yes  No  Unknown   Other (specify) 
 
Yes  No  Unknown  
 
 
Hospitalized:  1. Yes  2. No   9. Unknown   Name of hospital: ____________________ 
 
Clinical outcome: 1. Dead: date of death __/____/___ 2. Survived  3. Lost to follow-up  9. Unknown  
 
Cause of death:   
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C. Epidemiological investigation 
Did the patient have contact with confirmed case of measles (within 7-18 days) or rubella (within 12–23 days) 
prior to rash onset? 1. Yes  2. No  9. Unknown  
If yes: 
Who (case ID/name):   
Where (country/address):   
When (dates):   
 
Were there confirmed cases of measles and/or rubella reported in the area prior to this case? 
1. Measles  2. Rubella  3. Both  4. No  9. Unknown  
 
Did the patient travel within 7–23 days before onset of rash? 1. Yes  2. No  9. Unknown  
If yes: 
Where (country/address):   
When (dates):   
Travel details:   
 
Is the case epidemiologically linked to imported confirmed case? 1. Yes  2. No  9. Unknown  
If yes: 
Who (case ID/name):   
Where (country/address):   
When (dates):   
 
Was the case in contact with a pregnant woman since development of the symptoms? 
1. Yes  2. No  9. Unknown   If yes, please provide name and address   
__________________________________________________________________________________ 
 
D. Laboratory investigation 
Specimen collected: 1. Yes  2.No   3. Unknown  
If yes, type of specimen: 
Serum    Saliva/oral fluid    Nasopharyngeal swab   Dry blood spot  
 Urine   EDTA whole blood   Other       
 Date of specimen collection: / /    Date specimen sent to lab: / /   
 
Measles IgM: Not tested  Positive  Negative  In process  Indeterminate  
Rubella IgM: Not tested  Positive  Negative  In process  Indeterminate  
Date of laboratory result (first validated result): / /   
 
Measles virus detection: Not tested  Positive  Negative  In process  Genotype   
Rubella virus detection: Not tested  Positive  Negative  In process  Genotype   
 
E. Final classification 
0 Discarded  
1 Measles – laboratory-confirmed  2 Measles – epidemiologically linked  3 Measles – clinical  
6 Rubella – laboratory-confirmed  7 Rubella – epidemiologically linked  8 Rubella – clinical  
Source of infection: 1. Imported  2. Endemic  3. Import-related  9 Unknown  
Date of final classification: / /   
Investigated by: Name ___________________________________________________________ 
Position:  _________________________________________________________________
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Annex II Measles and rubella database for 
case-based reporting – CISID 
    Example of coding fields, definitions and possible entry field data types  
Field name Label Definition Possible entry Rules 
CaseID CaseID Unique identifier for the 
case 
Free text (limit of 50 
characters) 
(Country code) (prov- 
ince code) (district code) 
(year)(case number). 
Example of EPID numbers: 
RU204602006003 
(Russian 
Federation, St Petersburg 
city, case number 3) 
IniDiag Initial diagnosis Initial diagnosis 
1 Clinical measles 
2 Clinical rubella 
3 Other 
9 Unknown 
 
AreaID Country; first 
administrative level; 
second administrative 
level 
One code defines country 
and first and second 
administrative levels of 
residence of patient when 
illness was contracted 
Updated information 
can also be obtained in 
the “area code 
reference” function of the 
WHO Europe Web site 
A code defining at least the 
first administrative level 
must be provided 
DRash Date of onset of rash Date of onset of rash dd/mm/yyyy Must be reported in first 
report. Cannot be a future 
date: DRash must be on 
or after (>=) DBirth 
 
GenderID Gender Gender 1 Male 
2 Female 
4 Unknown 
Must be reported at first 
report 
Pregnant Pregnant Pregnant 1 Yes 
2 No 
9 Unknown 
 
DBirth Date of birth Date of birth dd/mm/yyyy Must be reported at first 
report if age at onset of 
rash is not provided. 
Cannot be a future date: 
DRash>=DBirth 
 
AgeAtRashOnset Age at rash onset Age at onset of rash Positive integer. Child is 
0 years until 1st birthday, 
1 year until 2nd birthday, 
etc. 
Must be reported at first 
report if date of birth is not 
provided 
NumOfVaccines Number of measles 
vaccines 
Number of measles 
vaccines from vaccination 
card or by verbal history 
Positive integer. Use 9 if 
the number of vaccines 
received is unknown 
 
Dvaccine Date of last measles 
vaccination 
Date of last measles 
vaccination 
dd/mm/yyyy Dvaccine>=Dbirth. Cannot 
be a future date 
NumOfRVaccines Number of rubella 
vaccines 
Number of rubella 
vaccines from vaccination 
card or by verbal history 
Positive integer. Use 9 if 
the number of vaccines 
received is unknown 
 
DRVaccine Date of the last rubella 
vaccination 
Date of the last rubella 
vaccination 
dd/mm/yyyy Dvaccine>=Dbirth. Cannot 
be a future date 
DNotification Date of notification Date when case is first 
reported or notified to public 
health authorities  
dd/mm/yyyy DNotification>=DBirth 
DNotification>=DRash 
Cannot be a future date 
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Field name Label Definition Possible entry Rules 
 
DInvestigation 
 
Date of investigation 
 
Date of epidemiological 
investigation of case by 
public health authorities 
 
dd/mm/yyyy 
 
DInvestigation>=DBirth 
DInvestigation>=DRash 
Cannot be a future date 
 
ClinFever 
 
Fever 
 
Presence of fever 
 
1 Yes 
2 No 
9 Unknown 
 
 
ClinCCC 
 
Cough or coryza or 
conjunctivitis 
 
Presence of one or more 
of cough, coryza or 
conjunctivitis 
 
1 Yes 
2 No 
9 Unknown 
 
 
ClinAAA 
 
Adenopathy, arthralgia/ 
arthritis 
 
Presence of one or more 
of adenopathy, arthralgia or  
arthritis 
 
1 Yes 
2 No 
9 Unknown 
 
 
ClinRashDuration 
 
Duration of rash 
 
Number of days when rash 
is present 
 
Positive integer. Use 
9 if duration of rash is 
unknown 
 
 
ClinOutcome 
 
Outcome 
 
Outcome of case. Death 
is defined as death 
due to measles or its 
complications within 
two months of onset of 
measles 
 
1 Death 
2 Alive 
3 Lost to follow-up or 
unknown 
 
 
ClinHospitalization 
 
Hospitalization 
 
Patient was hospitalized 
 
1 Yes 
2 No 
9 Unknown 
 
 
SrcInf 
 
Source of infection 
 
Case is part of a chain of 
transmission originating 
with an imported case 
 
1 Yes, imported 
2 Endemic 
3 Import-related 
9 Unknown 
 
 
SrcOutbreakRelated 
 
Outbreak-related 
 
Case is part of an outbreak 
 
1 Yes 
2 No 
9 Unknown 
 
 
SrcOutbreakID 
 
Outbreak ID 
 
Unique identifier for that 
outbreak 
 
Free text (limit of 50 
characters) 
 
Can only be filled in if 
SrcOut- 
breakRelated=1. When a 
case 
is part of an outbreak, the 
outbreak should be 
reported 
in the measles outbreak 
section. Unique identifier 
for 
that outbreak 
 
CompComplications 
 
Complications 
 
Patient had complications 
 
1 Yes 
2 No 
9 Unknown 
 
 
CompEncephalitis 
 
Encephalitis 
 
Patient suffered from 
encephalitis 
 
1 Yes 
2 No 
9 Unknown 
 
Answer is only possible if 
CompComplications=1 
 
CompPneumonia 
 
Pneumonia 
 
Patient suffered from 
pneumonia 
 
1 Yes 
2 No 
9 Unknown 
 
Answer is only possible if 
CompComplications=1 
 
CompMalnutrition 
 
Malnutrition 
 
Patient suffered from 
malnutrition 
 
1 Yes 
2 No 
9 Unknown 
 
Answer is only possible if 
CompComplications=1 
 
CompDiarrhoea 
 
Diarrhoea 
 
Patient suffered from 
diarrhoea 
 
1 Yes 
2 No 
9 Unknown 
 
Answer is only possible if 
CompComplications=1 
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Field name Label Definition Possible entry Rules 
 
CompOther 
 
Other 
 
Patient suffered from other 
complications 
1 Yes 
2 No 
9 Unknown 
 
Answer is only possible if 
CompComplications=1 
 
FinalClassification 
 
Final classification 
 
Final classification of the 
case 
 
0 Discarded 
1 Measles laboratory-
confirmed 
2 Measles 
epidemiologically linked 
3 Measles clinically 
6 Rubella laboratory-
confirmed 
7 Rubella 
epidemiologically linked 
8 Rubella clinically 
 
Should be provided 30 
days after date of onset of 
rash. Final classification 
can only be measles 
laboratory-confirmed if 
MeaslesIgM=1 or 
MeaslesVirusDetection=1 
or both. Final 
classification can only be 
rubella laboratory-
confirmed if 
RubellaIgM=1 or 
RubellaVirusDetection=1 
or both 
 
DSpecimen 
 
Date of collection 
 
Date when first specimen 
was collected from 
Patient regardless of test 
results 
 
dd/mm/yyyy 
 
DSpecimen>=DBirth 
DSpecimen+4days>= 
DRash. Cannot be a 
future date 
 
Specimens 
 
Type of specimen 
 
Type of specimen 
collected 
 
1 Serum 
2 Saliva/oral fluid 
3 Nasopharyngeal swab 
4 Dry blood spot 
5 Urine 
6 EDTA
6
 whole blood 
7 Other specimen 
 
Several types of 
specimen 
can be specified, 
separated by a comma 
Example: 1,2 means that 
a serum sample and a 
saliva sample have been 
taken 
 
DLabResult 
 
Date of laboratory result 
 
Date when laboratory 
results become available 
(first validated result) 
 
dd/mm/yyyy 
 
DLab Result>= DBirth 
DLabResult>=DSpecimen 
Cannot be a future date 
 
MeaslesIgm 
 
Measles IgM 
 
Validated result of measles 
IgM testing, whether on 
serum or oral 
fluid or other, at patient 
level 
 
0 Not tested 
1 Positive 
2 Negative 
3 In process 
4 Inconclusive 
 
 
MeaslesVirusDetection 
 
Measles virus detection 
 
Validated result of measles 
isolation or 
detection by, for example, 
RTPCR
7
 at patient level 
 
0 Not tested 
1 Positive 
2 Negative 
3 In process 
 
 
RRLMeaslesGenotype 
 
Measles virus genotype 
 
Measles virus genotypes 
 
Text 
 
 
RubellaIgm 
 
Rubella IgM 
 
Validated result of rubella 
IgM testing, whether on 
serum or oral fluid or 
other at patient level 
 
0 Not tested 
1 Positive 
2 Negative 
3 In process 
4 Inconclusive 
 
 
RubellaVirusDetection 
 
Rubella virus detection 
 
Validated result of rubella 
isolation or detection by, 
for example, RT-PCR at 
patient level 
 
0 Not tested 
1 Positive 
2 Negative 
3 In process 
 
 
RRLRubellaGenotype 
 
Rubella virus genotype 
 
Rubella virus genotypes 
 
Text 
 
 
CommentsEpi 
 
Comments 
 
Comments 
 
Free text. Should 
contain 
(if relevant): 1. whether 
case is the index case 
of an outbreak;2. name 
of country where patient 
acquired the disease  
 
                                                          
6
 EDTA – ethylenediaminetetraacetic acid  
7
 RT-PCR – reverse transcription polymerase chain reaction 
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Annex 3 Collection, storage and shipment of 
specimens for laboratory diagnosis 
and interpretation of results 
 
I. Clinical specimens for IgM and IgG antibody detection 
Clinical samples for the diagnosis and surveillance of measles and rubella should be obtained at the first 
contact between the patient with the clinical case and the health care system, irrespective of the stage of 
disease at which the patient presents. Depending on the country, blood obtained by venipuncture, dried 
capillary bloodspots on filter paper and/or oral fluid may be used. 
Fig. 1. Measles and rubella laboratory request and result form 
 
Country:_______________________Date:________________________Case ID:________________________________   
Patient Name:____________________________________ Gender M F Date of birth:________________   
Age in months:____________ Name of parent or guardian:_________________________________________________   
Address:__________________________________________________________________________________________  
Date of onset of rash:_________________________ Date of last vaccination for measles/rubella:___________________  
Case ID – unique identifier for the case should be obtained from epidemiologist. For date please use: dd-mm-yyyy (e.g. 20-10-2002). 
 
Specimen 
ID 
Specimen 
type 
Date of 
collection 
Date of 
shipment 
Date 
received 
at laboratory 
Condition Date of 
result 
Measles test Rubella test 
IgM Other* IgM Other* 
1           
2           
3           
 
Comment: _____________________________________*Other methodology (specify): ____________________________ 
___________________________________________________________________________________________________ 
 
Laboratory results should be sent to (name):_________________________________________________________________ 
Address: _____________________________________________________________________________________________ 
Telephone/ Fax number/E-mail____________________________________________________________________________ 
 
For use by the receiving laboratory:  
Name of laboratory: ____________________________________________________________________________________  
Name of the person receiving specimen: ___________________________________________________________________ 
 
Notes: 
a The Specimen No. should be exactly as written on the sample container. 
b Specimen type may include: serum, whole blood (ethylenediaminetetraacetic acid (EDTA), heparinized), dried blood spot, swab (oral fluid, throat, 
nasal), aspirate (nasopharyngeal, respiratory), urine (whole sample, pelleted) and others. 
c Additional comments of importance to the epidemiological investigation or the laboratory, such as: patient died; patient’s relationship to another case 
under investigation; second set of samples collected from same patient; samples exposed to suboptimal conditions prior to shipment. 
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I.A. Whole blood for IgM and IgG antibody detection 
Blood collection for serum by venipuncture and handling 
Blood should be collected in a sterile tube (5 ml for older children and adults and 1 ml for infants and 
younger children) and labelled with the patient’s name and/or identification number and the collection date.  
Whole blood can be stored at 4−8°C for up to 24 hours before the serum is separated, but it must not be 
frozen. 
Whole blood should be allowed to clot and then centrifuged at 1000 × gravitational units (g) for 10 minutes 
to separate the serum. If there is no centrifuge, the blood can be kept in a refrigerator (4–8oC) until there is 
complete retraction of the clot from the serum (no longer than 24 hours). 
The serum should be carefully removed with a fine-bore pipette to avoid extracting red cells, and 
transferred aseptically to a sterile vial labelled with the patient’s name or identifier, date of collection and 
specimen type. 
A measles/rubella laboratory request form should be fully completed when the specimen is collected and 
must accompany all specimens sent to the laboratory (Fig. 1). 
Storage and shipment of serum samples 
Serum should be stored at 4−8°C until shipment takes place, or for max. 7 days. 
When kept for longer periods, serum samples should be frozen at –20°C or lower and transported to the 
testing laboratory on frozen ice packs. Repeated freezing and thawing of serum samples for IgM testing 
should be avoided, as it may have detrimental effects on the stability of 
IgM antibodies. 
As a general rule, serum specimens should be shipped to the laboratory 
as soon as possible. The shipment should not be delayed for the 
collection of additional specimens. 
Serum specimens, in their uniquely labelled, sealed vials, should be 
placed in sealable plastic bags or pouches containing absorbent 
materials such as cotton wool to soak up any leakage that may occur 
(Fig. 2). 
Styrofoam boxes or an insulating (vacuum) flask should be used to 
contain the sealed  
bags or pouches. The specimen form and investigation form for each 
specimen should be placed in a separate plastic bag and taped securely 
to the inner surface of the top of the styrofoam box or the outside of the 
vacuum flask (Fig. 3). 
If ice packs (which should be frozen) are used, they should be placed at 
the bottom and along the sides of the styrofoam box. The samples 
should then be placed in the centre and more ice packs placed on top. 
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A shipping date should be arranged between the sample collectors and the laboratory. When arrangements 
have been finalized, the addressee should be informed of the time and manner of transportation. More 
details on the packaging and transportation of samples are provided in the Manual for the laboratory 
diagnosis of measles and rubella virus infection (1). 
 
I.B. Dried blood spots for IgM and IgG antibody detection 
Collection and handling of dried blood spots 
Clean each participant’s finger (or heel in the case of very young children) with alcohol and prick with a 
sterile, disposable microlancet. 
Collect up to four drops of whole blood on standardized filter paper (such 
as Whatman Chromatography paper no 3®, Schleicher and Schuell 
#903® or another high-quality paper). 
The filter paper should be marked up, either by hand or laser-printed, in a 
standard format that includes 14–15 mm circles within which to place the 
blood drops. Spaces should be marked to write the name, age and sex of 
the patient, with a space provided to write the laboratory or specimen 
number (Fig. 4). 
The filter paper should be allowed to dry thoroughly (for at least 60 minutes) at room temperature. Filter 
papers may be placed in a slide holder or similar receptacle during the drying process.  
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Storage and shipping of dried blood spots 
Each dried filter paper should be wrapped individually in paper, foil or plastic to prevent possible cross-
contamination. 
Filter papers should be stored away from sunlight and inside a plastic bag to protect them from dust and 
moisture. 
Dried blood spot samples are not considered biohazardous and can be shipped without special 
requirements or special documentation from the site of collection to the laboratory. 
Although samples do not need to be kept refrigerated or frozen during transport, it is advisable to store 
them in a cool place and transport them to the laboratory as soon as possible. 
 
I.C Oral fluid for IgM and IgG antibody detection 
Collection and handling of oral fluid 
Crevicular fluid exuded from the interface between the gums and teeth contains low levels of IgM. A 
number of swab collection devices (such as the Orocol®) have been developed specifically to collect this 
fluid from the mouth. 
The swabs are designed to be used like a toothbrush and should be rubbed along the gum until the swab is 
wet. This usually takes one minute. 
The wet swab should be placed inside the clear plastic transport tube, which has an area on the outside to 
write the name and details of the patient and the date of collection. 
Some devices have virus transport medium incorporated within the plastic transport tubes, while others 
require that a small volume of transport medium be added. Specific instructions provided by the 
manufacturer of the device should be followed. 
Storage and shipping of oral fluid 
Once a sample has been collected, the device should be sealed according to the manufacturer’s 
instructions. 
If the daily ambient temperature is below 22°C, samples should be shipped to the laboratory within 24 
hours. 
At higher temperatures samples should be kept in a refrigerator (4–8oC) until they can be shipped to the 
laboratory on ice. 
The samples are usually not considered biohazardous and can be shipped without special requirements or 
special documentation from the site of collection to the laboratory. 
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II. Clinical specimens for virus isolation 
Clinical samples for virus isolation should be collected as soon after onset of the rash as possible, and at 
least within seven days of onset. 
 
II. A. Urine for isolation of measles and rubella virus 
Collection of urine samples 
It is preferable to obtain the first urine passed in the morning. Urine (10–50 ml) should be collected in a 
sterile container and held at 4–8°C before centrifugation. 
Urine must not be frozen before the concentration procedure is carried out. A refrigerated centrifuge is 
recommended, but otherwise start with urine that has been chilled at 4°C. 
Urine should be centrifuged at 500 × g (approximately 1500 rpm) at 4°C for 5–10 minutes, preferably within 
24 hours after specimen collection. The supernatant should be discarded and the sediment resuspended in 
2–3 ml sterile transport medium, tissue culture medium or phosphate-buffered saline. 
If centrifugation facilities are not available, whole urine can be shipped directly to the laboratory in well-
sealed containers at 4°C immediately after collection. Do not freeze. 
Storage and shipping of urine samples 
The resuspended pellet may be stored at 4°C and shipped within 48 hours to a measles reference 
laboratory. 
Alternatively, it may be frozen at –70°C or lower in viral transport medium and shipped on dry ice in a well-
sealed screw-capped vial to protect against CO2 contamination. 
 
II. B. Nasopharyngeal specimens for isolation of measles and rubella virus 
Collection of nasopharyngeal samples 
Nasopharyngeal specimens may be taken as follows (in order of increasing yield of virus): 
• nasal aspirates are collected by introducing a few millilitres of sterile saline into the nose with a 
syringe fitted with fine rubber tubing and collecting the fluid in a screw-capped centrifuge tube containing 
viral transport medium; 
• throat washes are obtained by asking the patient to gargle with a small volume of sterile saline and 
collecting the fluid in viral transport medium; 
• nasopharyngeal swabs are obtained by firmly rubbing the nasopharyngeal passage and throat with 
sterile cotton swabs to dislodge epithelial cells; the swabs are placed in a sterile viral transport medium in 
labelled screw-capped tubes. 
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Storage and shipping of nasopharyngeal samples 
Nasopharyngeal specimens should be refrigerated and shipped at 4–8°C to arrive at the testing laboratory 
within 48 hours. 
If arrangements cannot be made for rapid shipment, swabs should be shaken in the medium for elution of 
the cells and then removed.  
The medium or nasal aspirate should be centrifuged at 500 × g (approximately 1500 rpm) at 4°C for five 
minutes and the resulting pellet resuspended in cell culture medium. 
The suspended pellet and the supernatant should be stored separately at –70°C or lower and shipped to 
the testing laboratory on dry ice in well-sealed screw-capped vials to protect against CO2 contamination. 
 
II.C. Whole blood for isolation of measles and rubella virus 
Collection of whole blood for virus isolation 
Measles virus is often detectable in peripheral blood mononuclear cells (PBMC) from a few days before to 
at least seven days after onset of rash. Samples collected for virus isolation should normally be collected 
as soon as possible and within two days of onset of rash. 
For isolation of PBMC for subsequent virus isolation, blood should be collected by venipuncture in a sterile 
tube supplemented with ethylenediaminetetraacetic acid (EDTA). A minimum blood volume of 5 ml is 
recommended. 
The plasma fraction can be used to determine the measles-specific IgM antibodies. The tube should be 
labelled with the patient’s identification number and the date of collection. 
Storage and shipment of whole blood 
Whole blood samples may be shipped in well-sealed tubes at 4°C. 
EDTA-supplemented whole blood should be processed for virus isolation within 48 hours after collection 
and must not be frozen at any time prior to processing. 
 
III. Samples for reverse transcription processing of specimens 
Although not recommended as a primary screening test, several laboratories have the capacity to use 
reverse transcription polymerase chain reaction (RT-PCR) for measles and/or rubella as a supplementary 
or confirmatory test. 
Any sample collected for virus isolation and transported to the laboratory can be used for RT-PCR analysis. 
Measles and rubella virus can often be detected by RT-PCR in whole blood (PBMC) for three to four days 
after onset of rash, and in urine and nasopharyngeal samples for a few days longer. 
Oral fluid and dried blood spots can be used for RT-PCR analysis if they have been collected within seven 
days of onset of rash (oral fluid even longer) and transported to the laboratory under nondenaturing 
conditions. 
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IV. Processing of specimens on arrival at the laboratory 
As each specimen is logged in, a laboratory identification number and information about the patient and the 
specimen should be recorded in the spreadsheet. The specimen information may be helpful in identifying 
problems that may contribute to difficulty with antibody detection and/or to loss of virus and inability to make 
isolations. Problems in shipment or with the samples should be reported to the sender.  
The following important data should be recorded:                 
 
 
Reference  
WHO Expanded Programme on Immunization. Manual for the laboratory diagnosis of measles and rubella 
virus infection, 2nd ed. Geneva, World Health Organization, 2006 
(http://www.who.int/immunization_monitoring/LabManualFinal.pdf, accessed 15 December 2012). 
 
Patient information Specimen information 
Case ID Specimen No. 
Age Type (urine/throat swab/nasal washing/blood) 
Date of birth Volume (urine) 
Date of onset of rash Condition/temperature on arrival 
Date of collection of sample(s) Action taken (centrifugation, storage location) 
IgM result  
Last measles and/or rubella 
vaccination date(s) 
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Annex 4 Measles/rubella aggregate outbreak 
reporting form 
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INSTRUCTION INSTRUCTIONS FOR FILLING IN THE MEASLES/RUBELLA AGGREGATE OUTBREAK 
REPORTING FORM FOR REPORTING OUTBREAKS TO WHO REGIONAL OFFICE FOR EUROPE 
Please report using routine ways – through the Regional Office or ECDC’s TESSy, as you do for reporting cases of 
measles or rubella disease, or for sending monthly reports. 
Please submit this form for each measles or rubella outbreak in your country. This form should be submitted as soon 
as an outbreak is reported, by the referent national surveillance health institution (the one in charge of outbreak 
response). A second, final report should be submitted when the outbreak is finished (following national regulation and 
epidemiology of disease) and should capture the most accurate and updated data. A minimum of two reports per 
outbreak should be sent. Additional updates may be sent if the country wishes.  
Outbreak identification 
Outbreak ID: Outbreak ID is used to identify, trace, match and update outbreak information. The ideal outbreak ID is 
MEA-CCC-YYYY-99. (CCC is 3 character ISO3 code of the country, YYYY is year of outbreak and 99 is series 
starting from 01 to number the outbreaks sequentially). 
Country: Enter the name of the country. 
1st and 2nd admin level: Specify the location of the outbreak onset. Enter the name of the first and second 
administrative level in the country, according to territorial organization (e.g. 1st level region, 2nd district; 1st level 
province, 2nd municipality; 1st level oblast, 2nd rayon.) 
Date of rash onset of first case: Indicate the date of rash onset for the index case. 
Date of rash onset of last case: Indicate the date of rash onset for the last case notified in the outbreak. [NOTE: This 
information should be indicated only in the final outbreak report.] 
Outbreak Notification Date: Indicate the date when the outbreak was notified to the referent surveillance health 
institution (e.g. reported by MD or health-care institution). Considering differences between the surveillance and health 
systems in Member States, this date should be the actual date when the planning and performing of outbreak control 
measures started in the referent institution. 
Current Outbreak Status: Indicate “Ongoing” or “Finished”. 
Outbreak end date: Indicate the date when outbreak finished. Considering differences between the surveillance and 
health systems in the Member States, as well different health regulations, the suggestion is to use date of the last 
case notification as the outbreak end date (if in the period of one maximal incubation for the outbreak causing disease 
there are no other notified cases). [NOTE: This information should be indicated in the final outbreak report.] 
Importation (Y/N): Indicate with “Yes” or “No” whether outbreak is imported from another country. Imported measles 
cases are cases exposed outside the country during the 7 to 18 days prior to rash onset as supported by 
epidemiological and/or virological evidence. If the index case came from or was exposed and infected by contact with 
a person from another administrative territory in the same country, that is NOT an importation. In the following cell of 
the form enter the name of the country where the index case was exposed. 
Case detail 
No. of suspected cases: (3 cells; Male, Female and Total) – indicate the number of suspected cases of measles or 
rubella by gender and as a total. A suspected case is any person who is under epidemiological, clinical and/or 
laboratory investigation during the outbreak, because of present clinical symptoms meeting the case definition for 
measles or rubella and/or a possible epidemiological link with another suspected/confirmed case. 
No. Deaths: Indicate the number of deaths caused by disease during the outbreak. 
No. Encephalitis: Indicate the number of cases diagnosed with encephalitis during the outbreak. 
No. Hospitalized: Indicate the number of cases hospitalized due to measles or rubella during the outbreak. 
Lab Detail 
No. Suspected cases with specimen: Indicate the number of suspected cases from whom specimens were 
collected for laboratory diagnostic procedures (detection of anti rubella or measles IgM). According to WHO 
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Guidelines for elimination of measles, rubella and congenital rubella syndrome (CRS), we expect that cases from the 
beginning of investigation (when cluster of cases is recognized) will be tested for both diseases (IgM for measles and 
IgM for rubella). Later, when outbreak is confirmed by IgM results, countries with low incidence of both diseases 
should continue with testing of suspected case for measles and rubella for DDg, regardless which disease is actually a 
cause of outbreak. Look for more information in surveillance guidelines.  
No. Lab conf. measles cases: Indicate the number of measles cases that are confirmed IgM positive. No. Lab conf. 
rubella cases: Indicate the number of rubella cases that are confirmed IgM positive. Genotype: Indicate the genotype 
of virus (with isolation or by PCR only), if performed. 
Only rubella cases 
This information should be provided for a rubella outbreak investigation AND for cases that are lab. confirmed rubella 
cases in measles outbreak investigation. 
No. Pregnant Women: Indicate the number of suspected rubella cases in pregnant women during the rubella 
outbreak OR indicate the number of confirmed rubella cases in pregnant women during the measles outbreak. 
No. WCBA: Indicate the number of suspected rubella cases in women of childbearing age during the rubella outbreak 
OR indicate the number of confirmed rubella cases in women of childbearing age during the measles outbreak. 
About report 
Name and contact detail of the person reporting this outbreak: Enter the contact information of the person that 
WHO Regional Office for Europe can contact if there is a need for additional information. 
Date of this report to WHO Europe: Indicate the date when this report was sent to WHO Regional Office for Europe. 
Epidemiological detail of confirmed cases (lab confirmed, epi linked and final clinical) 
Enter information about confirmed cases during the outbreak regarding their age and immunization status. This 
information should be only for the diseases causing the outbreak and the related immunization status (for example, 
not rubella lab-confirmed cases during a measles outbreak or rubella immunization status of cases). The totals for 
rows and columns will be automatically calculated. 
Description of outbreak 
Indicate the main epidemiological findings: any specificity regarding characteristics of affected institutions and 
communities, special populations, professional exposure, immunization status, age of cases, dominating diagnoses 
for hospitalization, high number of cases with severe form of disease or other epidemiologically important findings. 
Measures taken to prevent/control further spread of outbreak 
Indicate the main measures taken to prevent/control further spread of outbreak, the outbreak response measures (e.g. 
school immunization). If it is possible, in the final closing outbreak report form indicate the risk management measures 
and potential long-term measures that are based on the lessons learned during this outbreak. 
Subnational outbreak spread details (please provide if available) 
In the case that epidemiological and laboratory findings are able to link other measles or rubella outbreaks or clusters 
in other administrative territories of the country, please enter information following the title row of the table. Depending 
on national regulations, these cases may be considered as clusters of the reported outbreak or as individual 
outbreaks. If they are considered as separate outbreak(s), please enter this information in cell of “Comments” row and 
fill in the additional form for that outbreak(s). 
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Annex 5 Congenital rubella syndrome case 
investigation form 
Recommended basic set of data for case-based reporting in national surveillance system 
Fill in this form for investigation and reporting of a clinically suspected case of congenital rubella syndrome 
Case ID:   Region:    District:      
Date of notification: / / Date of investigation: / /  Date of reporting: / /   
 
A. Identification 
 
Name of the child:____________________________________ Sex:  Male   Female  
Date of birth:___ /___ /___ if not available – age in months_____ Address:__________________________ 
___________________________________________________________________________________________  
Place infant delivered:__________________________ Name of mother:__________________________________   
 
B. Clinical signs and symptoms 
Gestational age (weeks) at birth:______ Birth weight (grams): ___________________________  
Group A (please complete all) Group B (please complete all) 
Congenital heart disease: Y es  No  Unknown  Purpura: Yes  No  Unknown  
Cataracts: Yes  No  Unknown  Microcephaly: Yes  No  Unknown  
Congenital glaucoma: Yes  No  Unknown  Meningoencephalitis
: 
Yes  No  Unknown  
Pigmentary retinopathy: Yes  No  Unknown  Jaundice: Yes  No  Unknown  
Hearing impairment: Yes  No  Unknown Splenomegaly: Yes  No  Unknown  
    Developmental 
delay: 
Yes  No  Unknown  
    Radiolucent bone 
disease: 
Yes  No  Unknown  
 
Other abnormalities: Yes  No  If yes please describe:______________________________________ 
_________________________________________________________________________________________   
Name of physician who examined infant:_________________________________________________________ 
 City/town/village:___________________________________________ Telephone:_______________________ 
 Present status of infant: Alive   Dead  
If dead, cause of death: ______________________________________________________________________ 
Autopsy conducted: Yes   No    Unknown  
Autopsy findings:___________________________________________________________________________ 
Autopsy date:_____/____/_______   
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C. Maternal history/Antenatal care 
Number of previous pregnancies: Mother’s age (years):   
Vaccinated against rubella: Yes  No  Unknown  If yes, give date: ___/___/___  
Conjunctivitis: Yes  No  Unknown  If yes, date of onset___/___/___ 
  
Coryza: Yes  No  Unknown  If yes, date of onset___/___/___ 
Cough: Yes  No  Unknown  If yes, date of onset___/___/___ 
Maculopapular rash: Yes  No  Unknown  If yes, date of onset___/___/___ 
Lymph nodes swollen: Yes  No  Unknown  If yes, date of onset___/___/___ 
Arthralgia/arthritis: Yes  No  Unknown  If yes, date of onset___/___/___ 
Other complications Yes  No  Unknown  If yes, date of onset___/___/___ 
  
Was rubella laboratory-confirmed in the mother Yes  No  Unknown  
If yes, when (date): ___/___/___ 
Was the mother exposed during pregnancy to person of any age with maculopapular (e.g. not vesicular) rash 
illness with fever   Yes  No  Unknown   If yes, when (date): ___/___/___ 
Month of pregnancy:_______________________________Describe where:______________________ 
__________________________________________________________________________________ 
Did the mother travel during pregnancy: Yes  No  Unknown If yes, when (date): ___/___/___ 
Month of pregnancy:_______________________________ Describe where:______________________ 
__________________________________________________________________________________  
 
D. Infant/child laboratory investigations 
Specimen collected: Yes  No  Unknown    
If yes, type of specimen: Serum  Throat swab   Urine   Cerebrospinal fluid   Other   
Date of specimen collection: ___/___/___ Date specimen sent: ___/___/___ 
 
Rubella IgM:  Not tested  Positive  Negative  In process  Inconclusive  
Sustained IgG level*: IgG not tested  Yes   No  In process  
(*sustained IgG level on at least 2 occasions between 6 and 12 months of age) 
Rubella virus isolation: Not tested  Positive  Negative  In process  
Rubella PCR:   Not done  Positive  Negative  In process  Genotype_______    
Date of laboratory result (first validated result): ____/____/____ 
 
E. Final classification 
CRS   Discarded  If discarded, please specify:__________________________________________ 
Case classification as  Laboratory-confirmed   Epidemiologically linked  Clinical   
Classification by origin: Endemic  Imported   Import-related  Unknown    
Date of final classification: ____/____/____ 
Investigator:________________________________________________________________________________  
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Annex 6. Steps for establishing a CRS 
surveillance system 
 
1. Identify national CRS surveillance coordinators responsible for epidemiological and laboratory 
components of the system. 
Responsibilities of these coordinators include the following. 
Epidemiological coordinator oversees:  
 development of a protocol for CRS surveillance; 
 development of necessary training materials; 
 training on the CRS surveillance system; 
 monitoring of surveillance performance and data quality; 
 adequacy of collection and transportation of specimens for laboratory testing; 
 maintenance of the CRS surveillance database; 
 coordination with laboratory activities, to ensure linkage of laboratory and epidemiological data; 
 coordination of activities with national measles and rubella elimination programme in country, including 
reporting to WHO; 
 feedback on the CRS surveillance to participating health-care providers and facilities and relevant public 
health authorities. 
Laboratory coordinator oversees:  
 adequacy of laboratory testing, standard operating procedures (SOPs), necessary accreditations and an 
ongoing quality assurance programme; 
 interpretation and reporting of test results for CRS; 
 monitoring duration of virus shedding by CRS cases; 
 coordination with epidemiological activities, to ensure linkage of laboratory and epidemiological data; 
 laboratory-related training. 
 
2. Determine facilities at which infants with CRS are most likely to be seen. 
The facilities at which infants with most common defects associated with CRS – cataracts, heart defects, or deafness, 
as well as infants with maternal history of rubella during pregnancy – are likely to be seen should be included in the 
CRS surveillance system. As these defects are most likely to be evaluated and treated at secondary and tertiary care 
facilities, adequate sentinel surveillance for CRS can be conducted at these facilities, without including primary health-
care providers and facilities in the CRS surveillance system. This will help to avoid overwhelming general health-care 
providers with having to identify, report, and follow-up on cases of CRS. 
The types of facilities/providers most likely to evaluate and treat infants with CRS: 
 secondary care providers/facilities, particularly ophthalmologists, cardiologists, audiologists, neonatologists;  
 tertiary care facilities, particularly those that provide surgical services for the eyes, ears, and heart;  
 specialist care centres (e.g. children’s hospitals; centres for hearing and blindness); 
 obstetric centres or private clinics involved in the care of pregnant women with rubella. 
If providers and facilities included in the CRS surveillance system capture the majority of infants with suspected CRS 
within a country, the CRS surveillance system can be considered adequate. 
It is recommended that countries with newly established CRS surveillance systems pilot test their system with a few 
facilities to ensure adequacy of developed protocols and SOPs. Protocols may then be updated with feedback from 
the piloted sites. 
Responsibilities of local surveillance coordinators at sentinel sites include the following: 
 ensure adherence to the national protocol and SOPs for CRS surveillance; 
 assist as needed in training health-care providers and staff at the facilities concerned; 
 ensure collection of clinical and epidemiological data and completion of case investigation forms; 
 ensure appropriate collection and transportation of specimens with all relevant data, ensuring that laboratory 
data can later be linked to clinical and epidemiological information; 
 maintain a line listing of suspected CRS cases in the assigned facilities; 
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 provide periodic feedback for health-care providers at their respective sites; 
 maintain contact with the national coordinator regarding identification and follow-up of suspected cases of 
CRS identified in the area. 
 
3. Conduct initial and refresher training for participating providers. 
Training for providers from the sentinel facilities participating in CRS surveillance activities should be conducted on an 
annual basis, and more frequently as needed (e.g. for new staff). 
Training should include information regarding clinical features of CRS, evaluation of infants with suspected CRS, 
appropriate laboratory testing of suspected cases, follow-up of CRS cases, the importance of completing case 
investigation forms, infection control measures to prevent rubella virus spread from infants with CRS, and reporting 
cases in a timely manner. 
 
4. Initiate CRS surveillance activities. 
Reporting of suspected CRS cases should be initiated once the coordinator and participating sites have been 
identified and participating providers have been trained in SOPs for CRS surveillance. 
 
5. Conduct surveillance quality assessment and monitoring.  
Surveillance quality assessments need to be conducted at the sentinel sites at least every six months to assess 
completeness of CRS surveillance at the site: 
 this should be done by review of hospital records by the site-level coordinator to identify any missed cases; 
 missed cases can be identified by comparing the list of reported CRS cases with the list of all cases that meet 
the entry criteria for CRS surveillance (i.e. criteria for suspected CRS case); the proportion of missed cases at 
a sentinel site can be assessed as the percentage of missed cases identified by the coordinator, among all 
cases that meet the CRS surveillance entry criteria (total of both reported and unreported cases); 
 similarly, the proportion of suspected CRS cases that have been reported but have not been tested by 
laboratory can be assessed as the percentage of reported cases without laboratory testing among all reported 
suspected CRS cases (both tested and not tested).  
Monitoring surveillance data quality means that CRS surveillance case reports should be assessed for any missing 
variables. If records are incomplete, the findings should be discussed with providers at the site and the need for 
completeness of data and case reporting should be emphasized. 
 
6. Expand CRS surveillance and include other sites, as appropriate. 
In countries that have conducted limited pilot testing of CRS surveillance systems or in countries where assessments 
have shown that the majority of infants within the country are not included in CRS surveillance, the surveillance should 
be expanded to include more sites, with the ultimate goal of establishing sentinel site surveillance that captures the 
majority of infants in the country. 
  
7. Analyse the CRS surveillance data annually, or more frequently if necessary. 
Epidemiological variables that should be assessed include: 
 number of cases reported throughout time frame assessed (e.g. year);  
 case classification status;  
 geographical location of CRS cases within country; 
 whether or not cases were clustered and/or associated with rubella outbreaks; 
 maternal characteristics (age, race/ethnicity, country of birth); 
 location of maternal exposure to rubella. 
 
8. Provide feedback for stakeholders involved in the CRS surveillance system 
Feedback should include information on the status of the epidemiology of CRS, including, if necessary, any updates 
and recommendations for improvements. 
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